Enzymotec To Present New Findings Regarding Positive Effects Of INFAT® On Chinese Babies Stool And Behavior

MIGDAL HA'EMEQ, Israel, June 5, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that results of its clinical trial on INFAT® (structured fat ingredient for infant nutrition, marketed by Advanced Lipids, a joint venture of AAK and Enzymotec) will be presented at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Conference on June 9-12, 2014 in Jerusalem, Israel (to read the full scientific abstract go to: http://journals.lww.com/jpgn/Documents/ESPGHAN%202014%20Abstracts%20-%20Complete%20abstracts.pdf Page: 432).

Help employers find you! Check out all the jobs and post your resume.